Target intelligence / Profile preview

Sodium-dependent phosphate transport protein type IIb (NaPi-IIb)

Target
NaPi-IIb
Molecular classification
Transporter, Ion channel, Solute carrier (SLC) family member
01

Overview

Sodium-dependent phosphate transport protein type IIb (NaPi-IIb) is a membrane transporter that mediates the electrogenic cotransport of inorganic phosphate and sodium ions into cells, playing a central role in phosphate absorption, especially in the intestine and lung. The protein consists of 690 amino acids, with a molecular weight of approximately 75 kDa. It contains multiple transmembrane domains and is regulated by the parathyroid hormone and other factors. It is critical for systemic phosphate regulation, and its dysfunction leads to substantial disease phenotypes including pulmonary alveolar microlithiasis and altered bone formation. In cancer, NaPi-IIb serves as a tumor-associated antigen and is being pursued as a target for antibody-drug conjugate therapies in ovarian cancer.

Other names
NaPi-IIbNaPi2bSolute carrier family 34 member 2SLC34A2Sodium-phosphate transport protein 2BNaPi-2bNa(+)-dependent phosphate cotransporter 2BSodium/phosphate cotransporter 2B
02

Mechanism of action

Antibody-drug conjugate: Selective binding to NaPi-IIb on tumor cells delivers cytotoxic payload Inhibition or modulation of phosphate uptake via competitive or allosteric blockage (theoretical mechanism for small molecules, though clinical use is presently limited)

03

Biological functions

Phosphate homeostasisActive phosphate transport into cells via sodium cotransportRegulation of systemic phosphate balance, particularly in the intestine and lung
04

Disease associations

Cancer (notably ovarian cancer; NaPi-IIb is a tumor-associated antigen used in emerging therapeutics)Pulmonary alveolar microlithiasis (PAM), caused by loss-of-function mutations in SLC34A2, leading to phosphate accumulation in alveoliOther possible roles in disorders of phosphate metabolism and bone development
05

Safety considerations

Potential for off-target effects (expression outside tumor tissues in normal organs, e.g., lung, intestine)Disruptions in phosphate homeostasis (risk of hypophosphatemia with systemic inhibition)Lack of effective therapy for some diseases, e.g. PAM
06

Interacting drugs

Upifitamab rilsodotin

1 more in the full profile.

07

Biomarkers

NaPi-IIb protein expression in tumor tissues (e.g., ovarian cancer) for patient selection in precision oncologyGenetic variants in SLC34A2 for diagnosis of pulmonary alveolar microlithiasis

Beyond the preview

Go deeper on Sodium-dependent phosphate transport protein type IIb (NaPi-IIb).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sodium-dependent phosphate transport protein type IIb (NaPi-IIb).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call